Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein kinase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    157 result(s) found for: Protein kinase. Displaying page 4 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2020-000496-20 Sponsor Protocol Number: INCMGA0012-204 Start Date*: 2021-01-08
    Sponsor Name:Incyte Corporation
    Full Title: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemothe...
    Medical condition: Endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002155-17 Sponsor Protocol Number: LAP105594 Start Date*: 2008-04-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...
    Medical condition: Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004551-30 Sponsor Protocol Number: ICORG08-02Nilotinib Start Date*: 2008-10-31
    Sponsor Name:ICORG
    Full Title: A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in ...
    Medical condition: Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000061-21 Sponsor Protocol Number: I1V-MC-EIAN Start Date*: 2012-10-25
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study
    Medical condition: High Risk Vascular Disease (HRVD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10067825 Peripheral arterial disease LLT
    18.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    18.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    18.1 100000004852 10003602 Atherosclerosis cerebral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) AT (Completed) ES (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005141-32 Sponsor Protocol Number: MYL-1402O-3001 Start Date*: 2016-07-11
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous...
    Medical condition: Stage IV unresectable, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) HR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005252-14 Sponsor Protocol Number: KAI-9803-001 Start Date*: 2005-04-21
    Sponsor Name:KAI Pharmaceuticals Incorporated
    Full Title: Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI): Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coro...
    Medical condition: Acute myocardial infarction with ST elevation
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000891 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001361-29 Sponsor Protocol Number: CLWP 001 2008 Start Date*: 2009-10-08
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation
    Medical condition: chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005140-16 Sponsor Protocol Number: KAI-9803-004 Start Date*: 2009-06-02
    Sponsor Name:KAI Pharmaceuticals, Inc
    Full Title: Inhibition of δ-PROTEin kinase C for the reducTION of infarct size in Acute Myocardial Infarction (PROTECTION AMI)
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000891 Acute myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) HU (Completed) CZ (Completed) PT (Completed) BE (Completed) SE (Completed) FI (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004699-16 Sponsor Protocol Number: KRT-232-117 Start Date*: 2021-03-15
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukem...
    Medical condition: Phase 1b and Phase 2 Arms A and B: Adults with tumor protein 53 wild type (TP53wt) Philadelphia chromosome positive (Ph+) CML in chronic phase who are refractory or intolerant to ≥ 2 prior TKIs and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10009015 Chronic myeloid leukemia LLT
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    22.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000644-55 Sponsor Protocol Number: EFC16034 Start Date*: 2020-12-22
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) LV (Completed) SK (Completed) BE (Completed) NO (Completed) GR (Completed) NL (Completed) PT (Completed) HU (Completed) HR (Completed) IT (Completed) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000778-46 Sponsor Protocol Number: LiBiDi-EK314/11 Start Date*: 2013-01-17
    Sponsor Name:Forschungszentrum Jülich GmbH
    Full Title: Elucidation of Lithium Working Mechanism in Bipolar Disorder by means of Multi Modal Brain Imaging (LiBiDi)
    Medical condition: Healthy volunteers Bipolar patients type 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10043890 Tiredness LLT
    14.1 10017947 - Gastrointestinal disorders 10028821 Nausea with vomiting LLT
    14.1 10029205 - Nervous system disorders 10013575 Dizziness and giddiness LLT
    14.1 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    14.1 10018065 - General disorders and administration site conditions 10021689 Increased thirst LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036164 Poor weight gain LLT
    14.1 10029205 - Nervous system disorders 10044577 Tremor of hands LLT
    14.1 10029205 - Nervous system disorders 10027176 Memory loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004033-42 Sponsor Protocol Number: MKI102428 Start Date*: 2007-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) EE (Completed) FI (Completed) LT (Completed) SI (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005478-24 Sponsor Protocol Number: DYNE251DMD201 Start Date*: Information not available in EudraCT
    Sponsor Name:Dyne Therapeutics, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participan...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IE (Trial now transitioned) BE (Trial now transitioned) ES (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002882-35 Sponsor Protocol Number: CA180-018 Start Date*: 2006-03-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. Decision number of Paediatric Inves...
    Medical condition: Children and adolescents with CML in chronic, accelerated or blast phase who are resistant or intolerant to imatinib, or in first or subsequent relapse of Ph+ ALL after prior imatinib, or in second...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001266-17 Sponsor Protocol Number: DMD114349 Start Date*: 2011-08-08
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Prematurely Ended) FR (Ongoing) DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA BG (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002190-33 Sponsor Protocol Number: B1131004 Start Date*: 2012-02-02
    Sponsor Name:PFIZER, S.L.U.
    Full Title: A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA
    Medical condition: METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) CZ (Completed) DE (Prematurely Ended) GB (Completed) AT (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022770-13 Sponsor Protocol Number: ICORG10-01 Start Date*: 2011-01-12
    Sponsor Name:Cancer Trials Ireland
    Full Title: A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy
    Medical condition: Metastatic or unresectable renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001525-27 Sponsor Protocol Number: SNOXH94C201 Start Date*: 2012-07-19
    Sponsor Name:NOXXON Pharma AG
    Full Title: Phase IIa study to characterize the effects of the Spiegelmer® NOX-H94 on anemia of chronic disease in patients with cancer
    Medical condition: anemia of chronic disease in patients with cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10007050 Cancer LLT
    16.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003681-87 Sponsor Protocol Number: BMN-044-201 Start Date*: 2016-01-12
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A multi center, multi national, open label, extension study to evaluate the long-term efficacy and safety of BMN 044 (PRO044) in subjects with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001985-86 Sponsor Protocol Number: JX594-HEP024 Start Date*: 2016-09-29
    Sponsor Name:SillaJen Inc.
    Full Title: A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carc...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) without prior systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 07:14:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA